Patrick Flume to Forced Expiratory Volume
This is a "connection" page, showing publications Patrick Flume has written about Forced Expiratory Volume.
Connection Strength
1.541
-
Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis. Thorax. 2016 Mar; 71(3):223-9.
Score: 0.471
-
Efficacy and safety of inhaled dry-powder mannitol in adults with cystic fibrosis: An international, randomized controlled study. J Cyst Fibros. 2021 11; 20(6):1003-1009.
Score: 0.177
-
Continuous alternating inhaled antibiotics for chronic pseudomonal infection in cystic fibrosis. J Cyst Fibros. 2016 11; 15(6):809-815.
Score: 0.127
-
Forced Expiratory Volume in 1 Second Variability Helps Identify Patients with Cystic Fibrosis at Risk of Greater Loss of Lung Function. J Pediatr. 2016 Feb; 169:116-21.e2.
Score: 0.121
-
Early Life Growth Trajectories in Cystic Fibrosis are Associated with Pulmonary Function at Age 6 Years. J Pediatr. 2015 Nov; 167(5):1081-8.e1.
Score: 0.121
-
A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients. J Cyst Fibros. 2015 Jul; 14(4):507-14.
Score: 0.116
-
Testing two different doses of tiotropium Respimat? in cystic fibrosis: phase 2 randomized trial results. PLoS One. 2014; 9(9):e106195.
Score: 0.056
-
Voice and Respiratory Characteristics of Men and Women Seeking Treatment for Presbyphonia. J Voice. 2022 Sep; 36(5):673-684.
Score: 0.043
-
Predictors of pulmonary exacerbation treatment in cystic fibrosis. J Cyst Fibros. 2020 05; 19(3):407-414.
Score: 0.039
-
Standardized Treatment of Pulmonary Exacerbations (STOP) study: Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary Exacerbations. J Cyst Fibros. 2017 Sep; 16(5):600-606.
Score: 0.034
-
Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations. J Cyst Fibros. 2017 Sep; 16(5):592-599.
Score: 0.034
-
Rationalizing endpoints for prospective studies of pulmonary exacerbation treatment response in cystic fibrosis. J Cyst Fibros. 2017 09; 16(5):607-615.
Score: 0.034
-
A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients. J Cyst Fibros. 2016 07; 15(4):495-502.
Score: 0.031
-
Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial. Lancet Respir Med. 2015 Jul; 3(7):524-33.
Score: 0.030
-
Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N Engl J Med. 2015 07 16; 373(3):220-31.
Score: 0.030
-
Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study. Am J Respir Crit Care Med. 2012 Mar 15; 185(6):645-52.
Score: 0.023
-
Aerosolized antibiotic therapy for chronic cystic fibrosis airway infections: continuous or intermittent? Respir Med. 2011 Dec; 105 Suppl 2:S9-17.
Score: 0.023
-
Pulmonary complications after esophagectomy. Ann Thorac Surg. 2002 Mar; 73(3):922-6.
Score: 0.012
-
Psychological functioning of adults with cystic fibrosis. Chest. 2001 Apr; 119(4):1079-84.
Score: 0.011
-
The MUSC lung transplantation program: the first year's experience. J S C Med Assoc. 1995 May; 91(5):223-7.
Score: 0.007